LT2662380T - Ibandronato polimorfo a medicininis panaudojimas - Google Patents

Ibandronato polimorfo a medicininis panaudojimas

Info

Publication number
LT2662380T
LT2662380T LTEP13161008.1T LT13161008T LT2662380T LT 2662380 T LT2662380 T LT 2662380T LT 13161008 T LT13161008 T LT 13161008T LT 2662380 T LT2662380 T LT 2662380T
Authority
LT
Lithuania
Prior art keywords
medical use
ibandronate polymorph
ibandronate
polymorph
medical
Prior art date
Application number
LTEP13161008.1T
Other languages
English (en)
Inventor
Tim Sattelkau
Bernd Junghans
Uwe Eiermann
Bernhard Knipp
Original Assignee
Atnahs Pharma Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36090730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2662380(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnahs Pharma Uk Limited filed Critical Atnahs Pharma Uk Limited
Publication of LT2662380T publication Critical patent/LT2662380T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
LTEP13161008.1T 2005-02-01 2006-01-24 Ibandronato polimorfo a medicininis panaudojimas LT2662380T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05100686 2005-02-01

Publications (1)

Publication Number Publication Date
LT2662380T true LT2662380T (lt) 2019-03-12

Family

ID=36090730

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13161008.1T LT2662380T (lt) 2005-02-01 2006-01-24 Ibandronato polimorfo a medicininis panaudojimas

Country Status (25)

Country Link
US (1) US7714158B2 (lt)
EP (2) EP1848728B1 (lt)
JP (2) JP5828608B2 (lt)
KR (1) KR100908529B1 (lt)
CN (1) CN101111504B (lt)
AR (1) AR053012A1 (lt)
AU (1) AU2006210009B2 (lt)
BR (1) BRPI0607092A2 (lt)
CA (1) CA2594802C (lt)
CY (1) CY1121703T1 (lt)
DK (1) DK2662380T3 (lt)
ES (2) ES2712644T3 (lt)
HU (1) HUE042316T2 (lt)
IL (1) IL184562A (lt)
LT (1) LT2662380T (lt)
MX (1) MX2007009107A (lt)
NO (1) NO20073723L (lt)
PL (1) PL2662380T3 (lt)
PT (1) PT2662380T (lt)
RU (1) RU2368617C2 (lt)
SI (1) SI2662380T1 (lt)
TR (1) TR201902609T4 (lt)
TW (1) TWI374889B (lt)
WO (1) WO2006081963A1 (lt)
ZA (1) ZA200706168B (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713489B1 (en) 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
EP1848727B1 (en) * 2005-02-01 2015-06-17 F.Hoffmann-La Roche Ag Ibandronate polymorph b
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
WO2008004000A1 (en) * 2006-07-03 2008-01-10 Generics [Uk] Limited Novel process for the preparation of bisphosphonic acids
WO2008060609A1 (en) * 2006-11-16 2008-05-22 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7662990B2 (en) * 2007-04-11 2010-02-16 Hoffmann-La Roche Inc. Process for preparing ibandronate
JP2010524967A (ja) 2007-04-19 2010-07-22 ドクター・レディーズ・ラボラトリーズ・リミテッド イバンドロン酸ナトリウム多形体
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
EP2609101B1 (en) 2010-07-14 2015-01-28 Pharmathen S.A. Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
TR201200588A2 (tr) 2012-01-18 2012-07-23 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
KR20200085441A (ko) 2019-01-07 2020-07-15 엠에프씨 주식회사 이반드로네이트의 신규한 결정형 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
TW198039B (lt) * 1988-11-28 1993-01-11 Ciba Geigy Ag
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
ES2197677T3 (es) * 1998-10-16 2004-01-01 Akzo Nobel N.V. Composiciones de alta pureza que comprenden (7alfa-17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ona.
CA2353528C (en) 1998-12-04 2007-04-24 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
CN1404836A (zh) * 2001-09-14 2003-03-26 中生北方生物工程开发研究所 埃本膦酸钠作为预防和治疗骨质疏松症的药物的有效成分的应用
PL399493A1 (pl) 2002-05-10 2012-11-05 F. Hoffmann-La Roche Ag Kwasy bisfosfonowe do leczenia i profilaktyki osteoporozy
ES2291749T5 (es) 2002-12-20 2011-07-21 F. Hoffmann-La Roche Ag Formulación de altas dosis de ibandronato.
MX2007000087A (es) 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
EP1713489B1 (en) * 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof

Also Published As

Publication number Publication date
IL184562A (en) 2015-11-30
CA2594802A1 (en) 2006-08-10
TR201902609T4 (tr) 2019-03-21
KR100908529B1 (ko) 2009-07-20
MX2007009107A (es) 2007-09-11
RU2007132701A (ru) 2009-03-10
AU2006210009B2 (en) 2009-08-13
US20060172975A1 (en) 2006-08-03
CA2594802C (en) 2012-11-27
PL2662380T3 (pl) 2019-05-31
KR20070100394A (ko) 2007-10-10
ES2478302T3 (es) 2014-07-21
PT2662380T (pt) 2019-02-27
AR053012A1 (es) 2007-04-18
IL184562A0 (en) 2007-10-31
US7714158B2 (en) 2010-05-11
SI2662380T1 (sl) 2019-04-30
TWI374889B (en) 2012-10-21
CN101111504B (zh) 2011-12-21
WO2006081963A1 (en) 2006-08-10
EP2662380A1 (en) 2013-11-13
EP1848728B1 (en) 2014-06-11
JP5828608B2 (ja) 2015-12-09
DK2662380T3 (en) 2019-03-18
ES2712644T3 (es) 2019-05-14
JP6039754B2 (ja) 2016-12-07
CN101111504A (zh) 2008-01-23
CY1121703T1 (el) 2020-07-31
TW200638939A (en) 2006-11-16
JP2015205907A (ja) 2015-11-19
AU2006210009A1 (en) 2006-08-10
EP1848728A1 (en) 2007-10-31
ZA200706168B (en) 2008-09-25
JP2008529980A (ja) 2008-08-07
NO20073723L (no) 2007-08-28
EP2662380B1 (en) 2018-11-21
RU2368617C2 (ru) 2009-09-27
BRPI0607092A2 (pt) 2009-08-04
HUE042316T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
LT2662380T (lt) Ibandronato polimorfo a medicininis panaudojimas
GB0610680D0 (en) Therapeutic compounds
IL193678A0 (en) Therapeutic compounds
GB0603041D0 (en) Therapeutic compounds
HK1203925A1 (en) Therapeutic compounds
GB0504995D0 (en) Use of a compound
ZA200706170B (en) Ibandronate polymorph B
GB0606663D0 (en) Therapeutic compounds
EP1968603A4 (en) THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS
GB0615809D0 (en) Therapeutic compounds
GB0612971D0 (en) Therapeutic compounds
IL199697A0 (en) Therapeutical uses of eslicarbazepine
GB0625349D0 (en) Therapeutic compounds
EP2079704A4 (en) THERAPEUTIC COMPOUNDS
GB0625345D0 (en) Therapeutic compounds
GB0605573D0 (en) Therapeutic Compounds
GB0603455D0 (en) Therapeutic compounds
EP2114474A4 (en) MEDICAL PREPARATION
GB0608269D0 (en) Therapeutic compounds
GB2439923B (en) Therapeutic compounds
GB0611498D0 (en) Therapeutic compounds
GB0614082D0 (en) Therapeutic compounds
GB0604049D0 (en) Therapeutic compounds
GB0610670D0 (en) Therapeutic compounds
GB0615907D0 (en) Therapeutic Compounds